P. Michael Conn
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
P. Michael Conn has a total of 58 co-authors. Here are the top co-authors by number of shared publications:
Jo Ann Janovick
Divisions of Reproductive Sciences and Neuroscience, Oregon National Primate Research Center, Beaverton, OR, USA
24 shared publications- Shaun P. Brothers
Sylvester Comprehensive Cancer Center
8 shared publications Alfredo Ulloa-Aguirre
§Research Unit in Reproductive Medicine, Hospital de Ginecobstetricia “Luis Castelazo Ayala”, Instituto Mexicano del Seguro Social, México D.F., Mexico, and Oregon National Primate Research Center, Oregon Health Sciences University, Portland, OR, USA
7 shared publicationsAnda Cornea
Divisions of Reproductive and Developmental Sciences and Neuroscience (J.A.J., A.C., P.M.C), Cell Biology and Development, and Obstetrics and Gynecology, Oregon Health and Science University, Beaverton, Oregon 97006-3448
6 shared publicationsPaul E. Knollman
Divisions of Neuroscience and Reproductive Biology, ONPRC/OHSU, Oregon National Primate Research Center, 505 NW 185th Avenue, Beaverton, Oregon 97006, USA
5 shared publicationsGuadalupe Maya-Núñez
Research Unit in Reproductive Medicine, Hospital de Ginecobstetricia “Luis Castelazo Ayala”, Instituto Mexicano del Seguro Social, México D.F., Mexico
3 shared publications
Latest Publications
- 1 December 2013
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 381 (1-2) , 1-7
Species sequence differences determine the interaction of GnRH receptor with the cellular quality control system
- 1 December 2013
- Published by Elsevier in Molecular and Cellular Endocrinology
- Vol. 381 (1-2) , 1-7
Species sequence differences determine the interaction of GnRH receptor with the cellular quality control system
- Open Access
- 1 September 2013
- Published by Elsevier in SLAS Discovery
- Vol. 18 (8) , 930-937
High-Throughput Screen for Pharmacoperones of the Vasopressin Type 2 Receptor
- 1 September 2013
- Published by Elsevier in SLAS Discovery
- Vol. 18 (8) , 930-937
Open AccessHigh-Throughput Screen for Pharmacoperones of the Vasopressin Type 2 Receptor
- Open Access
- 23 November 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 550
Gonadotropin-releasing hormone receptor activates GTPase RhoA and inhibits cell invasion in the breast cancer cell line MDA-MB-231
Gonadotropin-releasing hormone (GnRH) and its receptor (GnRHR) are both expressed by a number of malignant tumors, including those of the breast. In the latter, both behave as potent inhibitors of invasion. Nevertheless, the signaling pathways whereby the activated GnRH/GnRHR system exerts this effect have not been clearly established. In this study, we provide experimental evidence that describes components of the mechanism(s) whereby GnRH inhibits breast cancer cell invasion.
- 23 November 2012
- Published by Springer Nature in BMC Cancer
- Vol. 12 (1) , 550
Open AccessGonadotropin-releasing hormone receptor activates GTPase RhoA and inhibits cell invasion in the breast cancer cell line MDA-MB-231
Gonadotropin-releasing hormone (GnRH) and its receptor (GnRHR) are both expressed by a number of malignant tumors, including those of the breast. In the latter, both behave as potent inhibitors of invasion. Nevertheless, the signaling pathways whereby the activated GnRH/GnRHR system exerts this effect have not been clearly established. In this study, we provide experimental evidence that describes components of the mechanism(s) whereby GnRH inhibits breast cancer cell invasion.
- 24 August 2012
- Published by Springer Nature
- Vol. 63, 263-289
Pharmacological Chaperones Correct Misfolded GPCRs and Rescue Function: Protein Trafficking as a Therapeutic Target
G-protein-coupled receptors (GPCRs) are a large superfamily of plasma membrane proteins that play central roles in transducing endocrine, neural and sensory signals. In humans, more than 30 disorders are associated with mutations in GPCRs and these proteins are common drug development targets, with 30–50% of drugs targeting them. GPCR mutants are frequently misfolded, recognized as defective by the cellular quality control system, retained in the endoplasmic reticulum and do not traffic to the plasma membrane. The use of small molecules chaperones (pharmacological chaperones or “pharmacoperones”) to rescue misfolded GPCRs has provided a new approach for treatment of human diseases caused by misfolding and misrouting. This chapter provides an overview of the molecular basis of this approach using the human gonadotropin-releasing hormone receptor (hGnRHR) as model for treatment of conformational diseases provoked by misfolded GPCRs.
- 24 August 2012
- Published by Springer Nature
- Vol. 63, 263-289
Pharmacological Chaperones Correct Misfolded GPCRs and Rescue Function: Protein Trafficking as a Therapeutic Target
G-protein-coupled receptors (GPCRs) are a large superfamily of plasma membrane proteins that play central roles in transducing endocrine, neural and sensory signals. In humans, more than 30 disorders are associated with mutations in GPCRs and these proteins are common drug development targets, with 30–50% of drugs targeting them. GPCR mutants are frequently misfolded, recognized as defective by the cellular quality control system, retained in the endoplasmic reticulum and do not traffic to the plasma membrane. The use of small molecules chaperones (pharmacological chaperones or “pharmacoperones”) to rescue misfolded GPCRs has provided a new approach for treatment of human diseases caused by misfolding and misrouting. This chapter provides an overview of the molecular basis of this approach using the human gonadotropin-releasing hormone receptor (hGnRHR) as model for treatment of conformational diseases provoked by misfolded GPCRs.
- Open Access
- 1 July 2012
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 26 (7) , 1179-1188
Rescue of Misrouted GnRHR Mutants Reveals Its Constitutive Activity
G protein-coupled receptors (GPCR) play central roles in almost all physiological functions, and mutations in GPCR are responsible for over 30 hereditary diseases associated with loss or gain of receptor function. Gain of function mutants are frequently described as having constitutive activity (CA), that is, they activate effectors in the absence of agonist occupancy. Although many GPCR have mutants with CA, the GnRH receptor (GnRHR) was not, until 2010, associated with any CA mutants. The explanation for the failure to observe CA appears to be that the quality control system of the cell recognizes CA mutants of GnRHR as misfolded and retains them in the endoplasmic reticulum. In the present study, we identified several human (h)GnRHR mutants with substitutions in transmembrane helix 6 (F272K, F272Q, Y284F, C279A, and C279S) that demonstrate varying levels of CA after being rescued by pharmacoperones from different chemical classes and/or deletion of residue K191, a modification that increases trafficking to the plasma membrane. The movement of the mutants from the endoplasmic reticulum (unrescued) to the plasma membrane (after rescue) is supported by confocal microscopy. Judging from the receptor-stimulated inositol phosphate production, mutants F272K and F272Q, after rescue, display the largest level of CA, an amount that is comparable with agonist-stimulated activation. Because mutations in other GPCR are, like the hGnRHR, scrutinized by the quality control system, this general approach may reveal CA in receptor mutants from other systems. A computer model of the hGnRHR and these mutants was used to evaluate the conformation associated with CA.
- 1 July 2012
- Published by The Endocrine Society in Molecular Endocrinology
- Vol. 26 (7) , 1179-1188
Open AccessRescue of Misrouted GnRHR Mutants Reveals Its Constitutive Activity
G protein-coupled receptors (GPCR) play central roles in almost all physiological functions, and mutations in GPCR are responsible for over 30 hereditary diseases associated with loss or gain of receptor function. Gain of function mutants are frequently described as having constitutive activity (CA), that is, they activate effectors in the absence of agonist occupancy. Although many GPCR have mutants with CA, the GnRH receptor (GnRHR) was not, until 2010, associated with any CA mutants. The explanation for the failure to observe CA appears to be that the quality control system of the cell recognizes CA mutants of GnRHR as misfolded and retains them in the endoplasmic reticulum. In the present study, we identified several human (h)GnRHR mutants with substitutions in transmembrane helix 6 (F272K, F272Q, Y284F, C279A, and C279S) that demonstrate varying levels of CA after being rescued by pharmacoperones from different chemical classes and/or deletion of residue K191, a modification that increases trafficking to the plasma membrane. The movement of the mutants from the endoplasmic reticulum (unrescued) to the plasma membrane (after rescue) is supported by confocal microscopy. Judging from the receptor-stimulated inositol phosphate production, mutants F272K and F272Q, after rescue, display the largest level of CA, an amount that is comparable with agonist-stimulated activation. Because mutations in other GPCR are, like the hGnRHR, scrutinized by the quality control system, this general approach may reveal CA in receptor mutants from other systems. A computer model of the hGnRHR and these mutants was used to evaluate the conformation associated with CA.
- 1 August 2011
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 338 (2) , 430-442
Salt Bridges Overlapping the Gonadotropin-Releasing Hormone Receptor Agonist Binding Site Reveal a Coincidence Detector for G Protein-Coupled Receptor Activation
G protein-coupled receptors (GPCRs) play central roles in most physiological functions, and mutations in them cause heritable diseases. Whereas crystal structures provide details about the structure of GPCRs, there is little information that identifies structural features that permit receptors to pass the cellular quality control system or are involved in transition from the ground state to the ligand-activated state. The gonadotropin-releasing hormone receptor (GnRHR), because of its small size among GPCRs, is amenable to molecular biological approaches and to computer modeling. These techniques and interspecies comparisons are used to identify structural features that are important for both intracellular trafficking and GnRHR activation yet distinguish between these processes. Our model features two salt (Arg38-Asp98 and Glu90-Lys121) and two disulfide (Cys14-Cys200 and Cys114-Cys196) bridges, all of which are required for the human GnRHR to traffic to the plasma membrane. This study reveals that both constitutive and ligand-induced activation are associated with a “coincidence detector” that occurs when an agonist binds. The observed constitutive activation of receptors lacking Glu90-Lys121, but not Arg38-Asp98 ionic bridge, suggests that the role of the former connection is holding the receptor in the inactive conformation. Both the aromatic ring and hydroxyl group of Tyr284 and the hydrogen bonding of Ser217 are important for efficient receptor activation. Our modeling results, supported by the observed influence of Lys191 from extracellular loop 2 (EL2) and a four-residue motif surrounding this loop on ligand binding and receptor activation, suggest that the positioning of EL2 within the seven-α-helical bundle regulates receptor stability, proper trafficking, and function.
- 1 August 2011
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 338 (2) , 430-442
Salt Bridges Overlapping the Gonadotropin-Releasing Hormone Receptor Agonist Binding Site Reveal a Coincidence Detector for G Protein-Coupled Receptor Activation
G protein-coupled receptors (GPCRs) play central roles in most physiological functions, and mutations in them cause heritable diseases. Whereas crystal structures provide details about the structure of GPCRs, there is little information that identifies structural features that permit receptors to pass the cellular quality control system or are involved in transition from the ground state to the ligand-activated state. The gonadotropin-releasing hormone receptor (GnRHR), because of its small size among GPCRs, is amenable to molecular biological approaches and to computer modeling. These techniques and interspecies comparisons are used to identify structural features that are important for both intracellular trafficking and GnRHR activation yet distinguish between these processes. Our model features two salt (Arg38-Asp98 and Glu90-Lys121) and two disulfide (Cys14-Cys200 and Cys114-Cys196) bridges, all of which are required for the human GnRHR to traffic to the plasma membrane. This study reveals that both constitutive and ligand-induced activation are associated with a “coincidence detector” that occurs when an agonist binds. The observed constitutive activation of receptors lacking Glu90-Lys121, but not Arg38-Asp98 ionic bridge, suggests that the role of the former connection is holding the receptor in the inactive conformation. Both the aromatic ring and hydroxyl group of Tyr284 and the hydrogen bonding of Ser217 are important for efficient receptor activation. Our modeling results, supported by the observed influence of Lys191 from extracellular loop 2 (EL2) and a four-residue motif surrounding this loop on ligand binding and receptor activation, suggest that the positioning of EL2 within the seven-α-helical bundle regulates receptor stability, proper trafficking, and function.
- Open Access
- 1 January 2011
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 2, 9817
Pharmacoperone Identification for Therapeutic Rescue of Misfolded Mutant Proteins
G protein-coupled receptors (GPCRs), which includes the gonadotropin-releasing hormone (GnRH) receptor (GnRHR), comprises the largest family of validated drug targets – more than half of all approved drugs derive their benefits by selective targeting of GPCRs. Most drugs in this class are either agonists or antagonists of GPCRs and high throughput screens have typically been designed and performed with a view toward identification of such compounds as lead drug candidates. This manuscript presents the case that valuable drugs which effect the trafficking of GPCRs may have been overlooked because pharmacoperones have been selected from existing screens that identify agonists and antagonists. A “gain of activity assay” is proposed; this assay relies on the expression of a mutant of the GnRHR that is known to be rescuable by pharmacoperone drugs, and which is restored to activity in their presence. Accordingly, “hits” are identified by the appearance of activity. The gene for the mutant is under control of tetracycline and may be prevented from being expressed. This is a valuable feature since it allows false positives to be identified. Such drugs will show apparent activity whether or not the mutant is expressed. This assay will enable identification of these drugs from chemical libraries and does not rely on their activity as agonists or antagonists.
- 1 January 2011
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 2, 9817
Open AccessPharmacoperone Identification for Therapeutic Rescue of Misfolded Mutant Proteins
G protein-coupled receptors (GPCRs), which includes the gonadotropin-releasing hormone (GnRH) receptor (GnRHR), comprises the largest family of validated drug targets – more than half of all approved drugs derive their benefits by selective targeting of GPCRs. Most drugs in this class are either agonists or antagonists of GPCRs and high throughput screens have typically been designed and performed with a view toward identification of such compounds as lead drug candidates. This manuscript presents the case that valuable drugs which effect the trafficking of GPCRs may have been overlooked because pharmacoperones have been selected from existing screens that identify agonists and antagonists. A “gain of activity assay” is proposed; this assay relies on the expression of a mutant of the GnRHR that is known to be rescuable by pharmacoperone drugs, and which is restored to activity in their presence. Accordingly, “hits” are identified by the appearance of activity. The gene for the mutant is under control of tetracycline and may be prevented from being expressed. This is a valuable feature since it allows false positives to be identified. Such drugs will show apparent activity whether or not the mutant is expressed. This assay will enable identification of these drugs from chemical libraries and does not rely on their activity as agonists or antagonists.
- 1 January 2011
- Published by Elsevier
- Vol. 62, 109-141
Pharmacological Chaperones for Misfolded Gonadotropin-Releasing Hormone Receptors
- 1 January 2011
- Published by Elsevier
- Vol. 62, 109-141
Pharmacological Chaperones for Misfolded Gonadotropin-Releasing Hormone Receptors
- 1 March 2010
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 21 (3) , 190-197
Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs
- 1 March 2010
- Published by Elsevier in Trends in Endocrinology & Metabolism
- Vol. 21 (3) , 190-197
Trafficking of G-protein-coupled receptors to the plasma membrane: insights for pharmacoperone drugs